BioLok Obtains FDA Approval for Silhouette Laser-Lok Dental Implants

BioLok Obtains FDA Approval for Silhouette Laser-Lok Dental Implants
DEERFIELD BEACH, Fla.--(BUSINESS WIRE)--Oct. 25, 2004--BioLok International Inc. (OTCBB:BLLI) announced today that the FDA has approved Laser-Lok, a revolutionary Laser Micro-Machined surface on the collar of its Silhouette Tapered Implant System. The new surface induces soft tissue attachment that inhibits epithelial down-growth, has been shown to attach and retain bone adjacent to the implant while not reducing the plaque and inflammation related safety performance of Silhouette implants. BioLok's President & CEO, Bruce Hollander believes this new technology, that induces true "tissue engineering," is the first advancement in implant dentistry since Dr. Branemark's work in the 1970's.
"Laser-Lok allows the doctor to decide in advance where on the implant tissue should attach and where bone should attach. It is now possible to pre-engineer the biological width. Greatly superior restorative results can thus be attained. Our successful R&D team is now also applying this same technology to a new class of transcutaneous implants. We are extremely excited about these revolutionary developments." Silhouette Laser-Lok Implant will be available for sale on December 1, 2004.
Hollander said, "BioLok and Orthogen Corp., its wholly owned R&D division headed up by Harold Alexander, PhD, have been developing this surface for 13 years, with Clinical Studies completed in Rome, Italy by The Group For Implant Research, headed by Professor Gabriele Pecora." Additional Laser-Lok research has been contracted with the NYU School Of Dentistry where John Ricci, PhD, one of the inventors of the technology is now on faculty. These studies will have side by side comparisons of Silhouette Laser-Lok Implants to a number of competitor products.